Catalog No.	KDC25202
Product name	Emactuzumab ELISA Kit
Description	PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD115 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Emactuzumab in the sample competitively binds to the pre-coated protein with biotin-labeled Emactuzumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Emactuzumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications	Used for the quantitative determination of Emactuzumab concentration in serum and plasma.
Stability and Storage	When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Detection method	Colorimetric
Precision	Intra-Assay Precision (Precision within an assay): <20% Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision. Inter-Assay Precision (Precision between assays): <20% Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.   Intra-Assay Precision Inter-Assay Precision Sample 1 2 3 1 2 3 n 16 16 16 24 24 24 Mean (ng/mL) 7197.4 1658.1 354.1 7757.5 1737.2 441.6 Standard deviation 308.8 152.2 33.5 786.5 221.6 76.8 CV (%) 4.3 9.2 9.5 10.1 12.8 17.4
Sample type	Plasma, Serum
Assay type	Quantitative
Sensitivity	35.75 ng/mL
Range	234.38 - 15,000 ng/mL
Recovery	80-120%
Background	Emactuzumab, also known as RG-7155, is a humanized monoclonal antibody developed by Genentech/Roche. It was designed to directly against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R), which is also known as macrophage colony-stimulating factor receptor (M-CSFR) and Cluster of Differentiation 115 (CD115). Emactuzumab has been investigated in the treatment for the diseases including fallopian tube cancer, ovarian cancer, peritoneal cancer and solid tumors. The trail that emactuzumab combination regimen with selicrelumab (RG7876) in solid tumors is currently in Phase II.
Alternative Names	RG 7155, RO5509554, CAS: 1448221-67-7
Note	For Research Use Only.

AntibodySystem于2019年创立于法国，专注于生命科学研究领域蛋白、抗体及试剂盒的研发与生产。致力于为全球生命科学基础研究者提供高质量的科研试剂产品。
【核心产品线】 核心产品囊括：病毒/细菌相关抗体&蛋白、In Vivo功能性抗体、低背景流式抗体、高特异性纳米抗体、活性蛋白、PK/ADA试剂盒、特色小分子抗体、DNA/RNA抗体、传统多抗、经典内参及标签抗体。
【应用领域】 目前，旗下产品已全面覆盖热门病毒与超级细菌、寄生虫、肿瘤、老年痴呆（阿尔茨海默病）、帕金森、变态与过敏反应、免疫抑制与免疫激活等多个关键科研领域。
【产品优势】 高纯度、高特异性、高灵敏度重组蛋白、抗体以及ELISA 试剂盒。覆盖HRP、Biotin、FITC、PE、APC、PerCP等多种标记类型；适用于Human、Mouse、Rat、Rabbit、Goat等多个种属。 经WB、ELISA、IHC、IF、IP、FCM等多种实验验证，具有优异的特异性、灵敏度和批间一致性。产品常备现货，支持快速交付，并提供详实验证数据及高分文献支持，为肿瘤学、免疫学、细胞生物学及药物研发提供可靠研究工具。
如果您对我们的产品感兴趣,请联系027-65279366

以上产品仅用于科研,产品信息以产品说明书为准